Labcorp appoints Novartis U.S. President Victor Bulto to Board of Directors

LABCORP HOLDINGS INC.

Victor Bulto appointed to Labcorp's Board effective December 1, 2025; he is President of Novartis U.S. and member of Novartis Executive Committee.
Bulto brings 25 years of healthcare experience and oversees Novartis' $20B+ U.S. business across oncology, immunology, neuroscience, and cardiovascular-renal-metabolic areas.
CEO Adam Schechter stated Bulto's expertise in therapeutic areas and transformation will support Labcorp's innovation and long-term growth strategy.
Bulto will receive compensation consistent with Labcorp's director compensation program as described in the April 4, 2025 proxy statement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.